Tokyo Tape
Sign in
← Fukuda Denshi

Quarterly report · Q2

6960.TEDINET S100S7MX
Period2023-04-01 → 2023-09-30
Filed2023-11-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
MetricValuePeriodScopeSource row
Revenue¥66.5bn2023-04-01 → 2023-09-30Cons.Net sales
Revenue¥134.6bn2022-04-01 → 2023-03-31Cons.Net sales (5-year summary)
Revenue¥62.6bn2022-04-01 → 2022-09-30Cons.Net sales
Operating income¥14.0bn2023-04-01 → 2023-09-30Cons.Operating income
Operating income¥11.1bn2022-04-01 → 2022-09-30Cons.Operating income
Ordinary income¥14.1bn2023-04-01 → 2023-09-30Cons.Ordinary income
Ordinary income¥25.1bn2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥11.7bn2022-04-01 → 2022-09-30Cons.Ordinary income
Profit before tax¥14.3bn2023-04-01 → 2023-09-30Cons.Income before income taxes
Profit before tax¥11.8bn2022-04-01 → 2022-09-30Cons.Income before income taxes
Net income (owners)¥9.8bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥17.3bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥8.1bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income¥9.8bn2023-04-01 → 2023-09-30Cons.Profit loss
Net income¥8.1bn2022-04-01 → 2022-09-30Cons.Profit loss
Total assets¥210.8bnat 2023-09-30Cons.Assets
Total assets¥206.9bnat 2023-03-31Cons.Assets
Total assets¥196.9bnat 2022-09-30Cons.Total assets (5-year summary)
Total liabilities¥39.3bnat 2023-09-30Cons.Liabilities
Total liabilities¥43.9bnat 2023-03-31Cons.Liabilities
Net assets / equity¥171.5bnat 2023-09-30Cons.Net assets
Net assets / equity¥163.0bnat 2023-03-31Cons.Net assets
Net assets / equity¥155.1bnat 2022-09-30Cons.Net assets (5-year summary)
Cash and deposits¥70.5bnat 2023-09-30Cons.Cash and deposits
Cash and deposits¥68.0bnat 2023-03-31Cons.Cash and deposits
Cash & equivalents¥67.5bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥64.9bnat 2023-03-31Cons.Cash and cash equivalents
Cash & equivalents¥63.4bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥61.0bnat 2022-03-31dCons.Cash and cash equivalents
Operating cash flow¥10.4bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥23.1bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥11.3bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥4.8bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥14.2bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥6.5bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥3.2bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥5.6bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥3.1bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥324.322023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥208.782023-07-01 → 2023-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥571.252022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥268.432022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥174.152022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
Equity ratio81.3%at 2023-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio78.8%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio78.8%at 2022-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 30
SegmentItemPeriodValue
jpcrp040300-q2r_E02304-000Consumables And Other Productsreportable segmentrevenue2023-04-01 → 2023-09-30¥20.5bn
jpcrp040300-q2r_E02304-000Consumables And Other Productsreportable segmentrevenue external2023-04-01 → 2023-09-30¥20.5bn
jpcrp040300-q2r_E02304-000Consumables And Other Productsreportable segmentsegment profit2023-04-01 → 2023-09-30¥4.1bn
jpcrp040300-q2r_E02304-000Medical Treatment Equipmentreportable segmentrevenue2023-04-01 → 2023-09-30¥29.3bn
jpcrp040300-q2r_E02304-000Medical Treatment Equipmentreportable segmentrevenue external2023-04-01 → 2023-09-30¥29.3bn
jpcrp040300-q2r_E02304-000Medical Treatment Equipmentreportable segmentsegment profit2023-04-01 → 2023-09-30¥6.7bn
jpcrp040300-q2r_E02304-000Patient Monitoring Equipmentreportable segmentrevenue2023-04-01 → 2023-09-30¥3.8bn
jpcrp040300-q2r_E02304-000Patient Monitoring Equipmentreportable segmentrevenue external2023-04-01 → 2023-09-30¥3.8bn
jpcrp040300-q2r_E02304-000Patient Monitoring Equipmentreportable segmentsegment profit2023-04-01 → 2023-09-30¥737m
jpcrp040300-q2r_E02304-000Physiological Diagnostic Equipmentreportable segmentrevenue2023-04-01 → 2023-09-30¥13.0bn
jpcrp040300-q2r_E02304-000Physiological Diagnostic Equipmentreportable segmentrevenue external2023-04-01 → 2023-09-30¥13.0bn
jpcrp040300-q2r_E02304-000Physiological Diagnostic Equipmentreportable segmentsegment profit2023-04-01 → 2023-09-30¥2.4bn
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-09-30¥66.5bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-09-30¥66.5bn
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-09-30¥14.0bn
jpcrp040300-q2r_E02304-000Consumables And Other Productsreportable segmentrevenue2022-04-01 → 2022-09-30¥17.1bn
jpcrp040300-q2r_E02304-000Consumables And Other Productsreportable segmentrevenue external2022-04-01 → 2022-09-30¥17.1bn
jpcrp040300-q2r_E02304-000Consumables And Other Productsreportable segmentsegment profit2022-04-01 → 2022-09-30¥2.1bn
jpcrp040300-q2r_E02304-000Medical Treatment Equipmentreportable segmentrevenue2022-04-01 → 2022-09-30¥26.9bn
jpcrp040300-q2r_E02304-000Medical Treatment Equipmentreportable segmentrevenue external2022-04-01 → 2022-09-30¥26.9bn
jpcrp040300-q2r_E02304-000Medical Treatment Equipmentreportable segmentsegment profit2022-04-01 → 2022-09-30¥6.0bn
jpcrp040300-q2r_E02304-000Patient Monitoring Equipmentreportable segmentrevenue2022-04-01 → 2022-09-30¥5.2bn
jpcrp040300-q2r_E02304-000Patient Monitoring Equipmentreportable segmentrevenue external2022-04-01 → 2022-09-30¥5.2bn
jpcrp040300-q2r_E02304-000Patient Monitoring Equipmentreportable segmentsegment profit2022-04-01 → 2022-09-30¥881m
jpcrp040300-q2r_E02304-000Physiological Diagnostic Equipmentreportable segmentrevenue2022-04-01 → 2022-09-30¥13.4bn
jpcrp040300-q2r_E02304-000Physiological Diagnostic Equipmentreportable segmentrevenue external2022-04-01 → 2022-09-30¥13.4bn
jpcrp040300-q2r_E02304-000Physiological Diagnostic Equipmentreportable segmentsegment profit2022-04-01 → 2022-09-30¥2.1bn
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-09-30¥62.6bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-09-30¥62.6bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-09-30¥11.1bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 520
ItemContextValueUnit
Retirement benefit expenses sgaPrior1YTDDuration590000000JPY
Retirement benefit expenses sgaCurrentYTDDuration510000000JPY
Provision for directors bonuses sgaPrior1YTDDuration131000000JPY
Provision for directors bonuses sgaCurrentYTDDuration256000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q2r_E02304-000PhysiologicalDiagnosticEquipmentReportableSegmentsMember13417000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q2r_E02304-000PatientMonitoringEquipmentReportableSegmentsMember5202000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q2r_E02304-000MedicalTreatmentEquipmentReportableSegmentsMember26924000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q2r_E02304-000ConsumablesAndOtherProductsReportableSegmentsMember17084000000JPY
Revenues from external customersPrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember62628000000JPY
Revenues from external customersPrior1YTDDuration_ReconcilingItemsMember－JPY
Revenues from external customersPrior1YTDDuration62628000000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q2r_E02304-000PhysiologicalDiagnosticEquipmentReportableSegmentsMember－JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q2r_E02304-000PatientMonitoringEquipmentReportableSegmentsMember－JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q2r_E02304-000MedicalTreatmentEquipmentReportableSegmentsMember－JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q2r_E02304-000ConsumablesAndOtherProductsReportableSegmentsMember－JPY
Transactions with other segmentsPrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember－JPY
Transactions with other segmentsPrior1YTDDuration_ReconcilingItemsMember－JPY
Transactions with other segmentsPrior1YTDDuration－JPY
Net salesPrior1YTDDuration_jpcrp040300-q2r_E02304-000PhysiologicalDiagnosticEquipmentReportableSegmentsMember13417000000JPY
Net salesPrior1YTDDuration_jpcrp040300-q2r_E02304-000PatientMonitoringEquipmentReportableSegmentsMember5202000000JPY
Net salesPrior1YTDDuration_jpcrp040300-q2r_E02304-000MedicalTreatmentEquipmentReportableSegmentsMember26924000000JPY
Net salesPrior1YTDDuration_jpcrp040300-q2r_E02304-000ConsumablesAndOtherProductsReportableSegmentsMember17084000000JPY
Net salesPrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember62628000000JPY
Net salesPrior1YTDDuration_ReconcilingItemsMember－JPY
Net salesPrior1YTDDuration62628000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q2r_E02304-000PhysiologicalDiagnosticEquipmentReportableSegmentsMember2059000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q2r_E02304-000PatientMonitoringEquipmentReportableSegmentsMember881000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q2r_E02304-000MedicalTreatmentEquipmentReportableSegmentsMember6041000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q2r_E02304-000ConsumablesAndOtherProductsReportableSegmentsMember2087000000JPY
Operating incomePrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember11070000000JPY
Operating incomePrior1YTDDuration_ReconcilingItemsMember－JPY
Operating incomePrior1YTDDuration11070000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q2r_E02304-000PhysiologicalDiagnosticEquipmentReportableSegmentsMember13026000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q2r_E02304-000PatientMonitoringEquipmentReportableSegmentsMember3755000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q2r_E02304-000MedicalTreatmentEquipmentReportableSegmentsMember29279000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q2r_E02304-000ConsumablesAndOtherProductsReportableSegmentsMember20480000000JPY
Revenues from external customersCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember66541000000JPY
Revenues from external customersCurrentYTDDuration_ReconcilingItemsMember－JPY
Revenues from external customersCurrentYTDDuration66541000000JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q2r_E02304-000PhysiologicalDiagnosticEquipmentReportableSegmentsMember－JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q2r_E02304-000PatientMonitoringEquipmentReportableSegmentsMember－JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q2r_E02304-000MedicalTreatmentEquipmentReportableSegmentsMember－JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q2r_E02304-000ConsumablesAndOtherProductsReportableSegmentsMember－JPY
Transactions with other segmentsCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember－JPY
Transactions with other segmentsCurrentYTDDuration_ReconcilingItemsMember－JPY
Transactions with other segmentsCurrentYTDDuration－JPY
Net salesCurrentYTDDuration_jpcrp040300-q2r_E02304-000PhysiologicalDiagnosticEquipmentReportableSegmentsMember13026000000JPY
Net salesCurrentYTDDuration_jpcrp040300-q2r_E02304-000PatientMonitoringEquipmentReportableSegmentsMember3755000000JPY
Net salesCurrentYTDDuration_jpcrp040300-q2r_E02304-000MedicalTreatmentEquipmentReportableSegmentsMember29279000000JPY
Net salesCurrentYTDDuration_jpcrp040300-q2r_E02304-000ConsumablesAndOtherProductsReportableSegmentsMember20480000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2023-03-31pass
balance sheet identityconsolidated 2023-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-09-30pass